Welcome to our dedicated page for TuHURA Biosciences news (Ticker: HURA), a resource for investors and traders seeking the latest updates and insights on TuHURA Biosciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TuHURA Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TuHURA Biosciences's position in the market.
TuHURA Biosciences (NASDAQ:HURA) has entered into a definitive merger agreement to acquire Kineta, Inc. (OTC PINK:KANT), gaining rights to Kineta's novel KVA12123 antibody. The acquisition adds a Phase 2 novel checkpoint inhibitor to TuHURA's pipeline, with plans for a Phase 2a/b trial in mutated NPM1 AML in 2025.
KVA12123 is a VISTA-blocking immunotherapy administered as a monoclonal antibody infusion every two weeks. It has completed enrollment in its monotherapy arm, demonstrating safety at 1000mg dose level, and is finishing combination therapy trials with KEYTRUDA®. The transaction, following a $5 million exclusivity fee paid in July 2024, is expected to close in Q1 2025.
TuHURA Biosciences (Nasdaq: HURA) announced significant developments, including a Phase 3 accelerated approval registration trial for IFx-2.0 in first-line treatment of Merkel Cell Carcinoma, planned for first half of 2025. The company entered a non-binding letter of intent to acquire Kineta's KVA12123, a Phase 2 ready VISTA inhibiting antibody. TuHURA is advancing IFx-3.0, a tumor-targeted mRNA innate immune response agonist, and developing early discovery programs for bi-specific antibody drug conjugates. The company secured $31 million in financing through a merger with Kintara, funding operations into late 2025, and raised an additional $5 million for the potential Kineta acquisition.
TuHURA Biosciences (Nasdaq: HURA), a Phase 3 registration-stage immune-oncology company, announced its participation in the 2024 Maxim Healthcare Virtual Summit. Dr. James Bianco, President and CEO of TuHURA, was part of the Precision and Immune Oncology panel. The company focuses on developing novel technologies to overcome resistance to cancer immunotherapy. A webcast replay of the panel presentation is available for M-Vest members.
TuHURA Biosciences (NASDAQ:HURA), a Phase 3 registration-stage immune-oncology company, will present at the Virtual Investor "New to the Street" Event on October 30, 2024, at 4:00 PM ET. Dr. Jim Bianco, President and CEO, will provide a corporate overview and business outlook during a live moderated webcast.
Investors can submit questions live during the event, with the company aiming to answer as many as possible. The presentation will be available on TuHURA's website, with a replay accessible for 90 days following the live event.
TuHURA focuses on developing novel technologies to overcome resistance to cancer immunotherapy. This event offers an opportunity for investors to gain insights into the company's progress and future plans in the immune-oncology field.
TuHURA Biosciences has completed its merger with Kintara Therapeutics, creating a Phase 3 registration-stage immune-oncology company. The combined entity will operate as TuHURA Biosciences, Inc. and trade on Nasdaq under the ticker "HURA" starting October 18, 2024. The company's focus is on developing novel technologies to overcome resistance to cancer immunotherapy, with a lead program entering a single Phase 3 accelerated approval registration trial in the first half of 2025 for first-line Merkel Cell carcinoma treatment.
The merger includes a $31 million fully-funded financing, expected to support operations into late 2025. Post-merger, former Kintara equityholders own approximately 2.85% of the combined company, while TuHURA equityholders own about 97.15%. The company's pipeline includes Immune Fx (IFx) Innate Immune Response Agonists and Tumor Microenvironment Modulators, aimed at overcoming primary and acquired resistance to cancer immunotherapies.
FAQ
What is the current stock price of TuHURA Biosciences (HURA)?
What is the market cap of TuHURA Biosciences (HURA)?
